Informations

At ASH 2025, Prof. Jeff Sharman from the Willamette Valley Cancer Research Institute shares key clinical insights on mosunetuzumab, focusing on its safety, efficacy, and durability of response, particularly in…

At ASH 2025, Dr. Shannuo Li from the University of Utah, USA shares her perspective on emerging strategies for multi-target immune engagement, exploring the potential of simultaneously targeting BCMA, CD38,…

At the recent Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Cai Zhen and Professor He Jingsong from The First Affiliated Hospital, Zhejiang University School of Medicine, had 12 studies accepted, comprehensively showcasing systematic investigations in multiple myeloma ranging from basic research to clinical translation. These studies focused on…

Multiple myeloma is one of the most common hematologic malignancies, characterized by marked biological heterogeneity and a complex disease course. Achieving deep and durable remission at initial diagnosis is critical for improving long-term outcomes. At the recent Annual Meeting of the American Society of Hematology (ASH), Professor Du Juan’s study was selected for oral presentation,…

The 67th Annual Meeting of the American Society of Hematology (ASH) was held from December 6 to 9, 2025, in Orlando, bringing together the latest global advances in hematology research and clinical practice. At this year’s meeting, the team led by Professor Hu Kai from Beijing Gaobo Hospital presented seven studies focusing on CAR-T cell…